Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy-Reference-Cited by-同舟云学术

Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy

Published:2019-03 Issue: Volume:60 Page:37-46
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Tsai Jing-Jane¹,Ikeda Akio²,Hong Seung Bong³,Likasitwattanakul Surachai⁴,Dash Amitabh⁵^ORCID

Affiliation:

1. Department of Neurology; National Cheng Kung University Hospital and School of Medicine; National Cheng Kung University; Tainan City Taiwan

2. Department of Epilepsy, Movement Disorders and Physiology; Kyoto University Graduate School of Medicine; Kyoto Japan

3. Department of Neurology; Samsung Medical Center; Samsung Biomedical Research Institute; Samsung Medical Center and Samsung Advanced Institute for Health Sciences & Technology; Sungkyunkwan University School of Medicine; Seoul South Korea

4. Department of Pediatrics; Faculty of Medicine; Mahidol University; Bangkok Thailand

5. Eisai Singapore Pte. Ltd.; Singapore

Funder

Eisai Co., Ltd.

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/epi.14642/fullpdf

Reference27 articles.

1. Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review;Mac;Lancet Neurol,2007

2. World Health Organization Epilepsy, 2018: Rates of Disease http://www.who.int/news-room/fact-sheets/detail/epilepsy

3. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies;Yasuda;Clin Pharmacol Ther,2008

4. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions;Hung;Pharmacogenet Genomics,2006

5. Genetic predisposition of life-threatening antiepileptic-induced skin reactions;Chung;Expert Opin Drug Saf,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perampanel for the treatment of Asian people with epilepsy: Real-world evidence from the PERMIT extension study;Journal of the Neurological Sciences;2024-08

2. Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of primary generalized tonic–clonic seizures;Epilepsia;2024-06-12

3. Efficacy and safety of adjunctive perampanel treatment in pediatric patients with epilepsy aged 4–12 years: a real-world study;Journal of Neurology;2024-05-08

4. Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial;Clinical and Translational Science;2024-05

5. Long-term efficacy and safety of perampanel as an add-on therapy in patients with epilepsy;Epilepsy Research;2024-02